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Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may
interact with psilocybin’s antidepressant properties like other antidepressant drugs via
induction of neuroplasticity. The main aim of the study was to evaluate the effect of
psilocybin on sleep architecture on the night after psilocybin administration. Regarding the
potential antidepressant properties, we hypothesized that psilocybin, similar to other
classical antidepressants, would reduce rapid eye movement (REM) sleep and prolong
REM sleep latency. Moreover, we also hypothesized that psilocybin would promote slow-
wave activity (SWA) expression in the first sleep cycle, a marker of sleep-related
neuroplasticity. Twenty healthy volunteers (10 women, age 28–53) underwent two
drug administration sessions, psilocybin or placebo, in a randomized, double-blinded
design. Changes in sleep macrostructure, SWA during the first sleep cycle, whole night
EEG spectral power across frequencies in non-rapid eye movement (NREM) and REM
sleep, and changes in subjective sleep measures were analyzed. The results revealed
prolonged REM sleep latency after psilocybin administration and a trend toward a
decrease in overall REM sleep duration. No changes in NREM sleep were observed.
Psilocybin did not affect EEG power spectra in NREM or REM sleep when examined
across the whole night. However, psilocybin suppressed SWA in the first sleep cycle. No
evidence was found for sleep-related neuroplasticity, however, a different dosage, timing,
effect on homeostatic regulation of sleep, or other mechanisms related to antidepressant
effects may play a role. Overall, this study suggests that potential antidepressant
properties of psilocybin might be related to changes in sleep.
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and its active metabolite psilocin (4-hydroxy-N,
N-dimethyltryptamine) are the main psychoactive components
of psychedelic mushrooms. In the central nervous system,
psilocin acts as an agonist of serotonergic 5-HT1A and 5-
HT2A/C receptors, leading to altered states of consciousness
in humans (Tyls et al., 2014). Psilocybin doses of
0.04–0.43 mg/kg cause alterations in perception, cognition, and
emotions, while also eliciting long-term changes in well-being
and mood in both healthy and psychiatric subjects (Dos Santos
et al., 2016; Korčák et al., 2019; Barrett et al., 2020). These long-
lasting positive changes lead to an exploration of the therapeutic
potential of psychedelics as well as the mechanisms underlying
this potential. Because of its general safety, intermediate duration
of action, and therapeutic potential in several neuropsychiatric
disorders, psilocybin is currently the most intensely studied
psychedelic in clinical trials (Sewell et al., 2006; Grob et al.,
2011; Stebelska, 2013; Dos Santos, 2014).
Overall, there has been an increasing preclinical (Catlow et al.,
2013; Baumeister et al., 2014) and clinical (Carhart-Harris et al.,
2016; Bogenschutz and Ross, 2018) evidence for the
antidepressant potential of psilocybin. Although exact
mechanisms are currently unknown, it is generally believed to
be attributed to either a direct action on 5-HT receptors or the
psychological effects of acute intoxication (Carhart-Harris and
Goodwin, 2017). It has been shown that serotonergic psychedelics
including psilocybin via 5-HT2A receptors promote
neuroplasticity (Ly et al., 2018), a fundamental mechanism of
neuronal adaptation that is disrupted in depression (Carhart-
Harris and Goodwin, 2017) and restored by antidepressant
treatments including selective serotonin reuptake inhibitors
(SSRIs), tricyclic antidepressants (TCAs) or electroconvulsive
therapy (ECT) (Hayley and Littlejohn, 2013).
Synaptic plasticity and sleep display a close relationship.
Specifically, slow-wave activity (SWA), a marker of the
intensity of non-rapid eye movement (NREM) slow-wave sleep
(SWS), is hypothesized to actively maintain synaptic homeostasis
(Esser et al., 2007) and support memory functions dependent on
neuroplasticity (Buzsáki, 1998; Huber et al., 2004; Marshall et al.,
2006). According to the synaptic homeostasis hypothesis, SWA
reflects changes in synaptic strength and contributes to the
normalization of cellular homeostasis (Tononi and Cirelli,
2014). However, SWA expression is altered in patients with
depression (Kupfer et al., 1984; Benca et al., 1997; Plante
et al., 2012a; Plante et al., 2012b). Moreover, it has been
proposed that decreased neuroplasticity in depression, as well
as the efficacy of multiple depression treatments, may directly
depend on SWA expression (Goldschmied and Gehrman, 2019;
Rantamäki and Kohtala, 2020). Sleep is thus a plausible proxy to
evaluate synaptic plasticity and its induction by psilocybin and
other psychotropics in vivo.
Other sleep changes have been associated with the use of
antidepressant drugs. The most consistent effects of SSRIs, TCAs,
serotonin and norepinephrine reuptake inhibitors (SNRIs), and
monoamine oxidase inhibitors (MAOIs) have been reported on
REM sleep in terms of reduced duration and increased latency,
both after acute and chronic use (Wilson and Argyropoulos,
2005). However, the effect of sedating drugs like antidepressants
with antihistaminergic action, sedating TCAs, mirtazapine,
mianserin, or drugs with a strong antagonistic action at
serotonergic 5-HT2 receptors, like trazodone and nefazodone
is less pronounced showing little or no effect on REM sleep
(Wilson and Argyropoulos, 2005; Wichniak et al., 2017) while
decreasing sleep latency, improving sleep efficiency and
increasing SWS. NREM sleep changes such as increased delta
sleep ratio and time spent in SWS have been observed after longer
antidepressant treatment by sertraline (Jindal et al., 2003; Zhang
et al., 2013) but were not shown after a short use of SSRIs (Wilson
and Argyropoulos, 2005; Rasch et al., 2009; Tesler et al., 2013). As
most antidepressants alter and normalize REM sleep and SWS
changes in patients with depression, these sleep changes may be
directly associated with the observed antidepressant effects
(Wichniak et al., 2013; Wichniak et al., 2017; Rantamäki and
Kohtala, 2020).
Serotonergic psychedelics such as LSD, dimethyltryptamine
(DMT), and mescaline show sleep alterations including an
increase in wakefulness and inhibition of REM and NREM
sleep (Colasanti and Khazan, 1975; Kay and Martin, 1978).
Moreover, Ayahuasca, another serotonergic psychedelic
containing both DMT and MAOIs, caused a decrease in REM
sleep duration and a trend to increase REM latency while
enhancing SWA in the first sleep cycle after acute daytime
administration (Barbanoj et al., 2008). Analogously, ketamine,
a drug with rapid antidepressant effects and psychological side
effects is very similar to serotonergic psychedelics. A sub-
anesthetic infusion of 0.5 mg/kg ketamine has been shown to
enhance SWS duration and SWA, promote memory and
neuroplasticity, and increase the amount of REM sleep in
depressed patients (Duncan et al. 2013a; Duncan et al., 2017).
Despite the fact, that psilocybin is currently the most intensely
investigated psychedelic, the absence of any preclinical or
clinical sleep data after acute administration of psilocybin
represents a major knowledge gap related to its potential
antidepressant effect. Therefore, the primary aim of our
study was to evaluate changes in sleep associated with
psilocybin administration. More specifically, the study aimed
to identify how psilocybin changed both macro- and
microstructural sleep parameters to study both traditional
sleep stage measures as well as more detailed quantitative
aspects of sleep by conducting whole-night polysomnography
with 19 channels electroencephalography (EEG).
We hypothesized that, analogously to serotonergic
antidepressants (e.g., SSRIs) and serotonin agonists, psilocybin
would 1) prolong REM onset latency and 2) decrease the
proportion of REM sleep. In line with tenants of the synaptic
homeostasis hypothesis and findings from ketamine and
ayahuasca sleep studies, we also expected that 3) psilocybin
will increase SWA during the first sleep cycle where most
SWA occurs (Barbanoj et al., 2008; Duncan et al., 2013a;
Tononi and Cirelli, 2014). To study quantitative parameters of
sleep in more detail, spectral power was examined during the
whole night across multiple frequency bands during REM and
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NREM sleep stages. Lastly, as in ayahuasca research (Barbanoj
et al., 2008), no changes in the subjective perception of sleep
and no changes in objective sleep latency, total sleep time,
and sleep efficiency were expected. For exploratory purposes
only, ex post analyses were additionally conducted to control




All participants provided written informed consent before they
entered the study. The study was approved by the Ethical
Committee of the National Institute of Mental Health (NIMH-
CZ), by the State Institute for Drug Control and as a clinical trial
registered under the EudraCT No. 2012-004579-37.
Twenty healthy volunteers (10 women) aged 28–53 (mean 
36 ± 8.1 years) were enrolled in the present sleep experiment as
part of a larger ongoing study (for details: EudraCT No. 2012-
004579-37). Participants were included if they were free of regular
use of medication, had no major medical or psychiatric condition
present, no family history of psychotic disorder, no present sleep
disorder, and met other criteria as previously specified in
(Bravermanova et al., 2018). To control for the effect of female
hormonal changes on sleep and mood, our women volunteers
were tested at times not overlapping with their menses. Pregnant
women were excluded per protocol and we did not include any
menopausal or postmenopausal women. All participants were
asked to abstain from psychotropic drug use during the period
between the introductory interview and the experiment, excessive
alcohol use leading to drunkenness for 1 week before the
experiment. Participants were also asked to remain free of
coffee, tobacco, and food intake in the morning before the
experiment. One participant was excluded due to excessive
daytime sleepiness (recognized during the placebo EEG
session) and another two due to technical issues with
polysomnographic recordings. Data from a total of 17 subjects
were included in the final analysis.
Drug Administration
All volunteers participated in two sessions, one with an inactive
placebo and one with psilocybin (active drug) in a double-blind,
placebo-controlled crossover design (for details see Bravermanova
et al., 2018). Psilocybin was administered in 1 and 5mg capsules in
themorning of the experimental nights (around 9 am). The dose was
adjusted according to body weight (approximately 0.26 mg/kg). The
dose increased 1mg by every 5 kg of body weight and was thus
within the range of 15–22mg, mean  18.35 mg, s.d.  2.21. For
example, a person weighting 76–80 kg received a 20mg dose of
psilocybin. Psilocybin induced robust psychedelic effects with the
test period lasting approximately 6.5–8 h during which the
psychedelic effects dissipated. Participants came into the sleep
laboratory with no psychedelic effects present. Repeat sessions
occurred at a minimum of 28 days apart per protocol (mean 
49 days apart) after which any potential long-term effects of
psilocybin on sleep had presumably disappeared.
Polysomnography Recordings
In line with standards of good sleep research practice, all
participants except 2 volunteers underwent an adaptation
night at least 2 days before the beginning of the experiment
(median of 7.5 days). Whole-night polysomnography,
approximately 12 h after the placebo/psilocybin ingestion, was
performed using a gel cap with 19 electrodes according to the 10/
20 standard system with electrooculography (EOG),
electromyography (EMG, three submental electrodes), and
electrocardiography (ECG). Data were recorded using the
Brainscope polysomnography system (M&I spol. s.r.o., Czech
Republic) with a band-pass filter of 0.1–200 Hz and continuously
digitalized at a sampling rate of 1 kHz. Data were downsampled
to 250 Hz before further processing. Sleep scoring was provided
visually by two expert scorers blinded to the experimental
condition according to the AASM international criteria (Berry
et al., 2015). The interrater agreement reached 87%, Cohen’s
kappa was 0.82. In those recordings where the agreement did not
reach at least 80% level, a third blinded scorer acted as a tie-
breaker for inconsistent epochs.
Sleep Assessment
After each experimental night, subjective and objective sleep
characteristics were evaluated. Subjectively perceived sleep
latency, sleep duration, sleep quality were quantified using 4-
point Likert scales (one for “very poor,” four for “perfect”).
Objective sleep latency, sleep duration, sleep stage durations,
and sleep efficiency were computed.
An EEG spectral analysis was conducted using MATLAB (The
MathWorks, Inc, United States) with FIR filtering set at
0.5–40 Hz. All recordings were visually checked by four
experienced raters who manually rejected all 5-s epochs with
any of the following: electrode artifacts, muscle, or eye movement
artifacts. As a result, all NREM and REM sleep epochs were free of
eye movements and related artifacts which could bias spectral
estimates. A Fast Fourier transform (FFT) was then implemented
in 5-s epochs with a 50% overlap utilizing a standard hamming
window. Power spectra density for each 5-s artifact-free epoch
was derived following FFT calculation by the squaring of its
absolute values. Power spectra density was then averaged across
epochs for each channel and by each sleep stage. Resulting values
were then log-transformed and averaged across the following
defined frequency bands: delta (0.8–4.6 Hz), theta (4.6–8 Hz),
alpha (8–12 Hz), sigma (12–15 Hz), beta1 (15–20 Hz), beta2
(20–35 Hz) and absolute and relative power spectral values
were computed.
For the SWA analysis in the first sleep cycle, each recording
was visually checked and manually limited to the end of the
first cycle. Spectral analysis was then applied as described
above. To limit the number of comparisons, all 19 original
derivations were aggregated into respective average frontal,
central, parietal, temporal, and occipital areas, e.g., O1 and O2
channels were averaged into an occipital region. To directly
compare SWA in the first sleep cycle and SWA across the
whole night, all 19 original derivations were aggregated into an
average electrode.
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Statistical Analysis
Based on data distribution paired-samples t-tests or Wilcoxon
signed-rank tests were used to assess differences in all studied
sleep characteristics following daytime placebo and psilocybin
administration. EEG power spectral results were corrected for
multiple comparisons using the Sidak test (Šidák, 1967) for both
SWA analysis of the first sleep cycle and the whole night sleep
analysis (in all frequency bands across all 19 derivations
separately for each sleep stage). Effect sizes for both paired-
samples t-tests and Wilcoxon signed-rank tests were computed
using product-moment correlation coefficients (r) according to
(Rosenthal, 1991). For explorative purposes, a series of two-way
repeated measures ANOVAs was conducted ex post to find any
possible gender differences, with experimental condition
(psilocybin/placebo) as within subjects factor and gender
(female/male) as between subjects factor. Any significant
interactions between experimental condition and gender were
followed by post hoc tests (Bonferroni tests). All statistical
analyses were done using IBM SPSS Statistics 23 (IBM
Corporation, United States) MATLAB software, and Statistica
13 (TIBCO Software Inc., United States).
RESULTS
Effects of Psilocybin on Whole Night Sleep
Stage Architecture
Sleep latency, total sleep time, sleep efficiency, and the number of
sleep cycles were not significantly different in placebo and
psilocybin conditions (Table 1). A significant increase in REM
latency was found for the night after psilocybin administration,
z  −1.66, p  0.048 (1-tailed, uncorrected). The effect size was
small (r  −0.28). Sleep architecture in terms of duration or
proportion (% of total sleep time spent in the sleep stage) of sleep
stages did not differ significantly in the drug vs. placebo
conditions (Table 1). However, statistical trends for decreased
R, 1, and N3 duration and increased N2 proportion were
observed after psilocybin administration (uncorrected).
Effects of Psilocybin on SWA during the First Sleep
Cycle—A Proxy of Neuroplasticity
Absolute delta power during SWS in the first sleep cycle was
found to be significantly lower after psilocybin administration in
comparison to placebo at the average electrode (t (16)  −3.57, p 
0.003, r  0.67, medium effect), and locally at averaged frontal,
central, parietal, temporal and occipital derivations. After
correcting for multiple comparisons, a significant decrease
remained at averaged parietal (t (16)  −3.93, p  0.001),
temporal (t (16)  −3.40, p  0.004) and occipital (t (13) 
−3.26, p  0.006) derivations with large effect sizes (r  0.70, 0.65,
0.67 respectively). In relative delta power a significant decrease
was not observed at average electrode. However, it was locally
observed only in averaged occipital derivations (t (13)  −2.29,
p  0.039, r  0.54, large effect) in the psilocybin relative to the
placebo condition (Figure 1), although a trend decrease in EEG
relative delta power was also observed at the averaged central
derivations in the psilocybin relative to the placebo condition (t
(16)  −1.861, p  0.081, r  0.42, medium effect). After correcting
for multiple comparisons, no local changes remained significant
in relative spectral power.
Effects of Psilocybin on Sleep Microstructure—The
Whole Night EEG Power Spectra
The analysis of EEG power spectra revealed no significant
differences in power spectral density during N1, N2, N3, or R
sleep stages in either absolute or relative spectral power in any of the
defined frequency bands. However, in NREM overall (N1-N3) some
significant increases of relative but not absolute power were visible in
sigma band frontally and parietally (i.e., F4, P3, P4). No other
differences were observed in any other bands in NREM overall
(Figure 2). After correcting for multiple comparisons, no changes
remained significant in either absolute or relative spectral power in
all frequency bands at all 19 derivations. For average electrode, a
trend decrease after psilocybin administration in comparison to
placebo was found in absolute delta power (t (16)  −1.87, p  0.081,
r  0.42, medium effect) but not in relative delta power.
Effects of Psilocybin on Subjective Sleep
Measures
No significant changes in subjective total sleep time or sleep quality
were observed (Table 2). However, significant results were found in
subjective sleep latency where subjects perceived time to fall asleep
as longer (10.5 min on average) during the night after psilocybin
administration compared to placebo condition (t (18)  2.39, p 
0.028). This effect was medium-sized, r  0.49.
Gender Differences
Analyses revealed no main effects of gender nor significant
interactions between gender and experimental condition in
any of the sleep macrostructural properties (i.e., sleep latency,
REM latency, total sleep time, sleep efficiency, sleep cycles,
TABLE 1 | Sleep macrostructure after daytime administration psilocybin and
placebo (uncorrected).
Placebo Psilocybin p-Values
Sleep latencya (min ± SEM) 14.37 ± 2.37 21.68 ± 4.63 0.149
REM latencya,b (min ± SEM) 82.62 ± 5.05 115.05 ± 12.23 0.048
Total sleep time (min ± SEM) 400.28 ± 11.33 388.00 ± 12.98 0.315
Sleep efficiency (% ± SEM) 88.78 ± 2.14 88.75 ± 2.31 0.989
Sleep cycles (no. ± SEM) 4.06 ± 0.22 3.88 ± 0.22 0.565
N1 (% ± SEM) 3.39 ± 0.39 2.66 ± 0.26 0.101
N2 (% ± SEM) 42.62 ± 1.94 46.74 ± 2.41 0.051
N3 (% ± SEM) 22.53 ± 1.08 20.68 ± 1.66 0.175
R (% ± SEM)b 20.24 ± 1.52 18.48 ± 1.04 0.148
WASO (% ± SEM) 11.22 ± 2.14 11.24 ± 2.31 0.994
N1 (min ± SEM) 15.25 ± 1.72 11.63 ± 1.17 0.080
N2 (min ± SEM) 193.17 ± 10.27 205.13 ± 11.6 0.216
N3 (min ± SEM) 100.90 ± 4.18 90.37 ± 6.68 0.078
R (min ± SEM)b 90.90 ± 6.58 80.75 ± 4.83 0.095
WASO (min ± SEM) 50.28 ± 9.35 48.75 ± 9.78 0.878
aDenotes for non-normally distributed differences, non-parametric tests used.
bDenotes for 1-tailed tests.
N1, Stage 1 NREM sleep; N2, Stage 2 NREM sleep; N3, Stage 3 NREM sleep; R, REM
sleep; WASO, wake after sleep onset; SEM, standard error of the mean.
Values highlighted in bold are values significant at 0.05 level (uncorrected).
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individual sleep stages in min and %). In SWA during the first
sleep cycle, a significant main effect of gender was found in mean
relative delta power (across all electrodes) suggesting that women
had significantly higher relative delta power than men in our
sample, irrespective of experimental condition, F (1, 15)  4.584,
p  0.049. However, this effect was not found locally at frontal,
central, parietal, temporal, and occipital electrodes (corrected). In
subjective sleep parameters, only one significant interaction
between gender and condition was found, F (1, 12)  15.429,
p  0.002. Only men had significantly lower subjective sleep
quality after psilocybin administration.
DISCUSSION
As expected, the main finding of this study is that psilocybin
significantly increased REM sleep onset latency and showed a
trend toward reduced REM sleep duration on the first night after
FIGURE 1 | (A) Topographic plots of differences in t-values (Psilocybin–Placebo) in absolute delta power (left) and average absolute delta power in psilocybin (left
top) and placebo (left bottom) condition during the first SWS cycle, significant over averaged parietal, temporal and occipital derivations (corrected). (B) Topographic
plots as described in (A) for relative delta power with all differences non-significant. The yellow-red dot denotes areas significant at p < 0.01 (corrected).
FIGURE 2 | Topographic plots of differences in t-values (Psilocybin–Placebo) in absolute (top) and relative (bottom) spectral power for each frequency band in the
REM (top) and NREM (bottom) sleep across the entire sleep period. The yellow-red dot denotes electrodes significant at p < 0.05 (uncorrected). No differences
remained significant in both absolute and relative spectral power after correcting for multiple comparisons (Sidak method, all frequency bands, all 19 derivations).
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administration. These results are in line with the effects of SSRI,
SNRI, TCA, and MAOI antidepressants (Wichniak et al., 2017).
Serotonergic agonists without antidepressant effect, e.g.,
fenfluramine (Myers et al., 1993) or pergolide (Tagaya et al.,
2002) do not show such an effect. Shortened REM sleep onset
latency, increased REM sleep duration and increased REM
density have been previously considered as biological markers
of depression (Palagini et al., 2013), and their normalization was
associated with the reduction of depressive symptoms (Wichniak
et al., 2017). Thus, induced changes of REM sleep onset latency
observed in the present studymay be related to the antidepressant
effects of psilocybin where corresponding doses of psilocybin
(i.e., 10–25 mg) were administered (Carhart-Harris et al., 2016;
Carhart-Harris et al., 2017; Carhart-Harris and Goodwin, 2017).
Contrary to our expectations, psilocybin significantly decreased
absolute delta power during SWS in the first sleep cycle on the night
after psilocybin administration. From the neurochemical perspective,
our finding corresponds with the research on fenfluramine and other
5-HT2 receptor agonists that decrease SWA (Myers et al., 1993;
Monti, 2011). However, this result contradicts ketamine research,
which suggests increased SWA at the first night after treatment
(Barbanoj et al., 2008; Duncan and Zarate, 2013; Duncan et al., 2017).
The difference can be attributed to different neurochemical effects of
ketamine (Kapur and Seeman, 2002) or the shorter pharmacokinetics
after intravenous infusion of ketamine in comparison to the oral
presentation of psilocybin (Zanos et al., 2018; Korčák et al., 2019) and
thus to differing effects on the timing of plasticity processes.
Concurrently, Catlow et al. (2013) showed that the effects of
psilocybin on neurogenesis (the formation of new neurons, also
related to sleep) are dose- and time-related. It is thus possible that a
different dose or administration timing could affect the expression of
SWS, similarly as in SSRIs (e.g., sertraline) that increase SWS after
12 weeks of treatment (Jindal et al., 2003).
An alternative explanation for the present findings may be that
the acute effects of psilocybin cause a decrease in homeostatic
sleep pressure. Altered sleep pressure may in turn reflect
suppressed neural synchrony and/or recruitment of wider
cortical neural networks, processes that underlie plastic
changes related to synaptic homeostasis (Vyazovskiy et al.,
2011; Tononi and Cirelli, 2014). Lastly, present SWA changes
may also be explained by mechanisms other than neuroplasticity.
SWA suppression could normalize abnormally increased SWS
power in depression (Schwartz et al., 2001; Plante et al., 2012a)
and could relate to the improvement of depressive symptoms as
was previously shown using disruptive acoustic stimuli during
SWA (Landsness et al., 2011). Future research should investigate
whether psilocybin leads to SWA suppression in clinically
depressed populations and whether SWA changes relate to the
improvement of depressive symptoms.
To investigate qEEG changes of sleep after psilocybin
administration in general, a set of power spectral analyses was
conducted. On the first night after administration, psilocybin did
not affect EEG power spectra in NREM or REM sleep stages
robustly. The only differences were found in increases of relative
power in the sigma band in NREM sleep overall. Although these
differences did not remain significant after correction for multiple
comparisons and could be associated with the decrease of SWA
(Andrillon et al., 2011) in the present study, future research on
larger samples is warranted. Sigma activity has been associated
with sleep spindles which are believed to play an important role in
sleep maintenance protection as well as in memory consolidation,
synaptic plasticity (Astori et al., 2013), and depression (Nishida
et al., 2016; Sesso et al., 2017; Hamann et al., 2019).
Congruently with our expectations, psilocybin did not
significantly affect objective and subjective sleep continuity or
overall subjective sleep quality on the first night after
administration. The only parameter affected, a prolonged
subjective sleep latency, was comparable to that observed after
ayahuasca (Barbanoj et al., 2008). The tendency to the increased
proportion of N2 sleep is in line with reported acute effects of SNRI,
TCA (Wilson and Argyropoulos, 2005; Wichniak et al., 2017), and
fenfluramine (Myers et al., 1993). This change could be related to
decreases in REM and N3 sleep (Roehrs and Roth, 2010).
Despite no gender differences in sleep macrostructure were
found, the analysis of relative SWA delta power during the first
sleep cycle identified higher SWA in women, a finding consistent
with literature (Mourtazaev et al., 1995; Ehlers and Kupfer, 1997;
Carrier et al., 2001). Interestingly, the gender differences
interacting with psilocybin administration were found only in
subjective sleep quality. Women generally report more subjective
sleep problems than men (Reyner et al., 1995; Lindberg et al.,
1997; Groeger et al., 2004) which is an opposite trend as shown
after psilocybin administration. It is possible that psilocybin
worsens subjective quality in men. However, this result must
be treated with caution given low sample size.
Several limitations of the current study should be mentioned.
First, results could be influenced by the lack of statistical power
given our small sample size. However, our sample size is
comparable to other pharmaco-sleep research studies (e.g.,
(Barbanoj et al., 2008; Duncan et al., 2013b). Moreover, most
participants completed an adaptation night increasing the
reliability of sleep findings, and the within-subject design
allowed for a more efficient design in terms of statistical
power. Second, our study aimed only at a short-term effect on
sleep. It was thus not possible to detect any long-term sleep
changes during the days following the administration or changes
due to chronic or repeated psilocybin use. Third, the power
spectral analysis of REM sleep could be influenced by the
exclusion of phasic REM episodes which are characterized by
eye movements. However, ensuring precise EEG spectral
estimates free of confounding EOG artifacts was preferred.





18.75 ± 3.18 29.30 ± 4.87 0.028
Subjective total sleep timea
(min ± SEM)
430.00 ± 10.83 418.33 ± 13.60 0.408
Subjective sleep quality 3.29 ± 0.16 3.14 ± 0.21 0.480
Mean ± SEM (n  18).
Values highlighted in bold are values significant at 0.05 level (uncorrected).
aSubjective sleep latency differences not normally distributed, non-parametric tests used.
Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 6025906
Dudysová et al. Sleep Changes After Psilocybin
In conclusion, our study is the first to document that
psilocybin shows several expected sleep changes including
increased REM sleep onset latency and a trend to decreased REM
sleep duration following the first night after administration as
documented in serotonergic antidepressants (especially SSRIs).
Future research should explore psilocybin’s antidepressant
properties using measures of mood or antidepressant response after
administration and explore possible associations with sleep changes.
Our results did not confirm the assumption that psilocybin
would increase delta power during SWS in the first sleep cycle as
seen after ketamine administration (Duncan et al., 2017). Instead,
psilocybin acted as other 5-HT2 receptor agonists that decrease
SWS. Findings could reflect SWA alterations by mechanisms
other than neuroplasticity. Overall, our study supports the
potential role of psilocybin in sleep regulation and brings new
insight into the clarification of its antidepressant properties.
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